Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis

• Published in: Clinical and experimental gastroenterology Vol. 13; pp. 385 - 396
• Main Authors: Ogushi, Katsuaki, Chuma, Makoto, Uojima, Haruki, Hidaka, Hisashi, Numata, Kazushi, Kobayashi, Satoshi, Hirose, Shunji, Hattori, Nobuhiro, Fujikawa, Tomoaki, Nakazawa, Takahide, Wada, Naohisa, Iwasaki, Shuitirou, Fukushima, Taito, Sano, Yusuke, Ueno, Makoto, Kawano, Kuniyuki, Tsuruya, Kota, Shomura, Masako, Watanabe, Tsunamasa, Matsunaga, Kotaro, Kunishi, Yosuke, Saigusa, Yusuke, Irie, Kuniyasu, Iwabuchi, Shogo, Kako, Makoto, Morimoto, Manabu, Kagawa, Tatehiro, Tanaka, Katsuaki, Maeda, Shin
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2020; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: adverse events; Cancer therapies; Care and treatment; Chemotherapy; child-pugh; Clinical medicine; Complications and side effects; Drug dosages; Gastroenterology; Growth factors; Hepatocellular carcinoma; Hospitals; Lenvatinib; Liver; Liver cancer; Medical prognosis; Medical research; Medical schools; Original Research; overall survival; Patients; Regression analysis; Tumors; tyrosine kinase inhibitor; Japan; overall survival; Child-Pugh; adverse events; tyrosine kinase inhibitor; lenvatinib; hepatocellular carcinoma
• ISSN: 1178-7023; 1178-7023
• DOI: 10.2147/CEG.S256691

To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC). Patients with u-HCC who were treated with lenvatinib at multiple centers in Japan were retrospectively analyzed for treatment outcomes according to their respective CP status. Radiological objective response (OR) was assessed using modified response evaluation criteria in solid tumors (mRECIST) guidelines. Baseline demographic parameters were comparable between 126 (69.6%) patients with CP-A disease and 55 patients (30.4%) with CP-B disease. Frequency of lenvatinib-related adverse events, including decreased appetite (P=0.034), diarrhea (P=0.040), elevated serum bilirubin (P=0.016) and vomiting (P=0.009), were higher in CP-B than in CP-A patients. Relative dose intensity (RDI) was significantly higher in CP-A (0.69) than CP-B patients (0.50, P <0.001). Furthermore, OR rate (44.0%) was markedly higher in CP-A5 patients as compared to CP-A6 (25.5%), CP-B7 (22.2%), and CP-B8 patients (5.3%), respectively (P=0.002). In multivariable analysis, performance status (0 vs 1, 2, P=0.026), CP class (A vs B, P=0.045) and RDI (≥0.7 vs <0.7, P=0.034) were identified as factors associated with response to lenvatinib treatment. Overall survival (OS) at 12 months was significantly different between CP-A (66.3%) and CP-B patients (30.0%, P=0.002), and between CP 5-7 (59.2%) and CP 8 patients (34.8%, P=0.003). In multivariable analysis, CP class (A vs B, P=0.007) and Barcelona clinic liver cancer (BCLC) stage (B vs C, P=0.002) were associated with OS following lenvatinib treatment. Lenvatinib treatment offers significant benefits in patients with good liver function in real-world practice. The various characteristics identified in this study might be helpful as clinical predictors of response to lenvatinib and survival in clinical practice. Further studies are required to address eligibility for lenvatinib treatment in CP 7 patients.